Dr. Khleif on Next Steps to Take With Immunotherapy

Samir N. Khleif, MD
Published: Tuesday, Apr 19, 2016



Samir N. Khleif, MD, director, GRU Cancer Center, discusses next steps researchers and physicians need to take with immunotherapy in the field of oncology.

Although immunotherapy—specifically PD-1/PD-L1 agents—has helped propel the field forward and improve patient outcomes, they do not elicit responses in 100% of patients, Khleif explains. Additionally, a large percentage of patients who do respond have disease recurrence. The answer on how to enhance on this, he adds, is combination immunotherapy. 

In addition to standard therapy options, such as chemotherapy and immunotherapy, radiation therapy can also be utilized to created to create a systemic effect on tumors.

<<< View more from the 2016 AACR Annual Meeting



Samir N. Khleif, MD, director, GRU Cancer Center, discusses next steps researchers and physicians need to take with immunotherapy in the field of oncology.

Although immunotherapy—specifically PD-1/PD-L1 agents—has helped propel the field forward and improve patient outcomes, they do not elicit responses in 100% of patients, Khleif explains. Additionally, a large percentage of patients who do respond have disease recurrence. The answer on how to enhance on this, he adds, is combination immunotherapy. 

In addition to standard therapy options, such as chemotherapy and immunotherapy, radiation therapy can also be utilized to created to create a systemic effect on tumors.

<<< View more from the 2016 AACR Annual Meeting


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x